PTO/SB/08A (07-05) Approved for use through 07/31/2006. OMB 0651-0031

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE ton Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO

Sheet 1

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Use as many sheets as necessary)

Complete if Known Application Number 09/903,412 Filing Date July 11, 2001 First Named Inventor Shohei Koide Art Unit 1639 **Examiner Name** Teresa D. Wessendorf Attorney Docket Number 17027.003US1

Examiner Cite Initials* No.	Cite	Document Number	Publication Date	Name of Patentee or	Pages, Columns, Lines, Where
	NO.	Number-Kind Code ^{2 (# known)}	MM-DD-YYYY	Applicant of Cited Document	Relevant Passages or Relevan Figures Appear
Tow		^{US-} 6,348,584	02-19-2002	Hodgson et al.	
ŕ		^{US-} 6,673,901	01-09-2004	Koide	
4		^{US-} 6,703,199	03-09-2004	Koide	
		^{US-} 6,462,189	10-08-2002	Koide	
		^{US-} 6,391,855	05-21-2002	Blaschuk et al.	
		^{US-} 6,818,418	11-15-2004	Lipovsek et al.	
<i>i</i> –		US- 2003/0027319	02-06-2003	Koide	
		^{US-} 2003/0108948	06-12-2003	Koide	
		^{US-} 2003/0134386	07-17-2003	Koide	
•		^{US-} 2003/0170753	09-11-2003	Koide	
		^{US-} 2003/0186385	10-02-2003	Koide	
11/		^{US-} 2004/0259155	12-23-2004	Chan et al.	
\mathbb{V}	-	^{US-} 2005/0038229	02-17-2005	Lipovsek et al.	· · · · · · · · · · · · · · · · · · ·
		US-			
		US-			<u> </u>

		FORE	IGN PATENT DOCL	JMENTS		
	Cite No.1	Foreign Patent Document	Publication Date	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages	Γ
		Country Code ³ Number ⁴ Kind Code ⁵ (<i>if known</i>)		Typinam of Once Document	Or Relevant Figures Appear	7
TOW		WO-94/24278	10-27-1994	Davis, Claude		T
4		WO-95/27045	10-12-1995	Smith, Rodger.G.		Г
		WO-94/18221	08-18-1994	Barbas et al.		Г
_4		WO-98/56915	12-17-1998	Koide, Shohei		Г
þ		WO-00/34784	06-15-2000	Lipovsek, Dasa		Г
J K.		JP-8-511417	03-12-1996	Davis et al.		一

Examiner				 			_
		1/1	$\overline{}$	Date		6 1	
Signature	F	<i>v , , , , , , , , , , , , , , , , , , ,</i>		Considered	l /か	Do. 12	
•	1 - 1	\smile	/ 1	Considered	10	P4/03	
						/ /~	

*EXAMINER: Initial if reference considered, whether of not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next conglunication to applicant. 'Applicant's unique citation designation number (optional). 2 See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. 3 Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3), 4 For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. 5 Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. Applicant is to place a check mark here if English language Translation is attached.

Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

Approved for use through 07/31/2006. OMB 0651-0031

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE
Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMR control number.

Substitute for form 1449/PTO	Complete if Known		
	Application Number	09/903,412	
INFORMATION DISCLOSURE	Filing Date	July 11, 2001	
STATEMENT BY APPLICANT	First Named Inventor	Shohei Koide	
(Use as many sheets as necessary)	Art Unit	1639	
	Examiner Name	Teresa D. Wessendorf	
Sheet 2 of 25	Attorney Docket Number	17027.003US1	

Examiner Cite Document Number Initials* No.1		U. S. PATENT D Publication Date	Name of Patentee or	Deces Column 12 140	
Initials*	No.1	Number-Kind Code ^{2 (# known)}	MM-DD-YYYY	Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevan Figures Appear
		US-			- I I I I I I I I I I I I I I I I I I I
		US-			
		US-	 		
		US-	 		
		US-	1		
		US-			
		US-			
		US-	1		
		US-			
		US-			
		US-	 		
		US-			
		US-	 		

Cite For	FORE	IGN PATENT DOC	UMENTS		_
Cite For	oreign Patent Document	Publication Date	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages	Γ
Cour	ountry Code ³ "Number ⁴ "Kind Code ³ (if known)	MM-DD-YYYY	The state of the s	Or Relevant Figures Appear	ゼ
) wc	O-01/64942	09-07-01	Lipovsek et al		┢
WC	O-04/019878	03-11-04	Afeyan et al.		
wc	O-05/056764	06-23-05	Chen et al.		r
 					
 			·		
	•				

Examiner	-				
		11111 1	Date		6 1
Signature	/ (<i>//</i> ·	Miscusof	Considered	1 10 1	つん ハー
			Considered	1 ''	20/03

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. Applicant's unique citation designation number (optional). 2 See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. 3 Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). 4 For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. 5 Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. Applicant is to place a check mark here if English language

Transation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

Approved for use through 07/31/2006. OMB 0651-0031

	U.S. Patent and Trademark Office; U.S.	
Hadaalla Barra ad B. L. M. A. A. A. A.	The state of the s	A DEL VILLIMITION OF COMMERCE
Under the Paperwork Reduction Act of 1995, no persons are requin	ed to respond to a collection of information unless it one	toine a wild OMB and access

Substitute for form 1449			e required to respond to a collection of information unless it contains a valid OMB control number. Complete if Known		
[Application Number	09/903,412	
INFORMAT		•	Filing Date	July 11, 2001	
STATEMEN	STATEMENT BY APPLICANT			Shohei Koide	
(Use as ma	ny sheets as n	ecessary)	Art Unit	1639	
			Examiner Name	Teresa D. Wessendorf	
Sheet 3	of	25	Attorney Docket Number	17027.003US1	

	_	NON PATENT LITERATURE DOCUMENTS			
Examiner Cite No.1		Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.			
TOW		Alzari et al., "Three-dimensional structure of antibodies," Annu. Rev. Immunol., 1998, 555-580			
1		Archer et al., "An alternative 3D NMR technique for correlating backbone 15N with side chain Hb resonances in large proteins," J. Magn. Reson., 1991, 95:636-641			
		Aukhil et al., "Cell-and heparin-binding domains of the hexabrachion arm identified by tenascin," J. Biol. Chem. 1993, 268:2542-2553			
		Barbas, C.D., et al., "Semisynthetic combinatorial antibody libraries: A chemical solution to the diversity problem", Proc. Natl. Acad. Sci. USA, 89, 4457-4461 (1992).			
,		Barbas, C.F., et al., "Assembly of combinatorial antibody libraries on phage surfaces: The gene III site", Proc. Natl. Acad. Sci. USA, 88, 7978-7982 (1991).			
ğ		Baron, M., et al., "Protein modules", TIBS, vol. 16, 13-17, (Jan. 1991).			
		Baron et al., "H NMR assignment and secondary structure of the cell adhesion type III module of fibronectin," Biochemistry, 1992, 31:2068-2073			
-		Bass et al., "Hormone phage: An enrichment method for variant proteins with altered binding properties," Proteins: Struct. Funct. Genet., 1990, 8:309-314			
		Bax and Grzesiek, "Methodological advances in protein NMR," Acc. Chem. Res., 1993, 26:131-138			
		Bazan, J.F., "Structural design and molecular evolution of a cytokine receptor superfamily", Proc. Natl. Acad. Sci. USA, vol. 87, 6934-6938, (Sep. 1990).	· · · · · · · · · · · · · · · · · · ·		

Examiner	7 10	_		
) <i>(/)</i>	-9	Date	10 66 1 -
Signature	, D	//	Considered	10/10/1
ALLANDICO I	22.440		Completice	

^{*}EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

considered. Include copy of this form with next communication for applicant.

1 Applicant's unique citation designation number (optional). 2 Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO:

PTO/SB/08B (07-05) Approved for use through 07/31/2006. OMB 0651-0031

17027.003US1

Under the Paperwork Reduction Act of 1995, no persons ar	o.s. Pater re required to respond to a collection	on of information unless it contains a valid OMB control number.
abstitute for form 1449/PTO		Complete if Known
	Application Number	09/903,412
NFORMATION DISCLOSURE	Filing Date	July 11, 2001
TATEMENT BY APPLICANT	First Named Inventor	Shohei Koide
(Use as many sheets as necessary)	Art Unit	1639
	Examiner Name	Teresa D. Wessendorf

Attorney Docket Number

Sheet 4

25

of

Examiner	Cite	NON PATENT LITERATURE DOCUMENTS Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of	$\overline{}$
Initials* No.		the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T
Tole		Becktel and Schellman, "Protein stability curves," Biopolymer 1987, 26:1859-1877	
		Berggard et al., "Fragment complementation studies of protein stabilization by hydrophobic core residues," Biochemistry, 2001, 40:1257-1264	
4		Bhat et al., "Bound water molecules and conformational stabilization help mediate an antigen-antibody association," Proc. Natl. Acad. Sci. USA, 1994, 91:1089-1093	
		Bork, P., et al., "Proposed acquisition of an animal protein domain by bacteria", Proc. Natl. Acad. Sci. USA, 89, 8990-8994 (1992).	
(•	Bork, P., et al., "Review: The Immunoglobulin Fold—Structural Classification, Sequence Patterns and Common Core", J. Mol. Biol., vol. 242, 309-320, (1994).	
1		Billeter et al., "Precise vicinal coupling constants 3JHNa in proteins from nonlinear fits of J-modulated [15N, 'H]-COSY experiments," J. Biomol. NMR, 1992, 2:257-274	
1		Bodenhausen and Ruben, "Natural abundance nitrogen-15 NMR by enhanced heteronuclear spectroscopy," Chem. Phys Lett. 1980, 69:185-189	
		Boder and Wittrup, "Yeast surface display for screening combinatorial polypeptide libraries," Nat Biotechnol., 1997, 15:553-557	
1		Boder and Wittrup, "Yeast surface display for directed evolution of protein expression, affinity, and stability," Methods Enzymol., 2000, 328:430-444	

Examiner	TI	77	Date	13	120	1
Signature	1:0.		Considered	10	140	101-
PEVALUATED. 1-	Mint M and a second day of	1 41 / 1 41 41				

^{*}EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

considered, include copy of this form with next communication to applicant.

1 Applicant's unique citation designation number (optional). 2 Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO:

Approved for use through 07/31/2006, OMB 0651-0031 U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

	Substitute for form 1449/PTO		re required to respond to a collection	Complete if Known		
				Application Number	09/903,412	
INF	ORMATION	DIS	CLOSURE	Filing Date	July 11, 2001	
STA	ATEMENT E	BY A	PPLICANT	First Named Inventor	Shohei Koide	
	(Use as many she	ote se s	pressand	Art Unit	1639	
				Examiner Name	Teresa D. Wessendorf	
Sheet	5	of	25	Attorney Docket Number	17027.003US1	J

		NON PATENT LITERATURE DOCUMENTS	
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T²
TH		Burke et al., Phage display of peptides and proteins, 1996, (Kay et al., Ed.), pp. 305-326, Academic Press, San Diego	
,		Burgess et al., The Journal of Cell Biology 111:2129-38, 1990.	
		Campbell, I.C., et al., "Building proteins with fibronectin type III modules", Structure, vol. 2, 333-337, (May 15, 1994).	
,		Chen et al., "Mapping the binding interfaces of the proteins of the bacterial phaphotransferase system, HPr and IIAglc," Biochemistry, 1993, 323:32-37	
		Chen et al., "Characterization of the WW Domain of Human Yes-associated Protein and Its Polyproline-containing Ligands," J. of Biol. Chem., 1997, 272(27):17070-17077	
		Clarke et al., J Mol Biol., 1997, 270:771-778	
1		Clakson, T., et al., "In vitro selection from protein and peptide libraries", Trends in Biotechnology, 12, 173-184 (1994).	
1		Clore, G.M., et al., "Structures of Larger Proteins in Solution: Three-and Four-Dimensional Heteronuclear NMR Spectroscopy", Science, 252, 1390-1399 (1991).	
1		Conrath et al., "Camel Single-domain antibodies as modular building units in bispecific and bivalent antibody constructs," J. Biol. Chem. 276(10):7346-7350 (2001).	-
-			

Examiner	+ n M	Date	10/11
Signature	1.0.	Considered	10/4/05

^{*}EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

considered. Include copy of this form with next communication to applicant.

1 Applicant's unique citation designation number (optional). 2 Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.98. The Information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

Substitu	Substitute for form 1449/PTO			Complete if Known		
				Application Number	09/903,412	
			CLOSURE	Filing Date	July 11, 2001	
STA	ATEMENT E	BY A	PPLICANT	First Named Inventor	Shohei Koide	
	(Use as many she	ets as n	lecessarvi	Art Unit	1639	
	(200 20 1111 11 11 11 11 11 11 11 11 11 11 11			Examiner Name	Teresa D. Wessendorf	
Sheet	6	of	25	Attorney Docket Number	17027.003US1	

		NON PATENT LITERATURE DOCUMENTS	
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
TAU		Connolly, "Solvent-accessible surfaces of proteins and nucleic acids," Science, 1983, 221:709-713	
•		Cordingley et al., "Substrate requirements of human rhinovirus 3C protease for peptide cleavage in vitro," J Biol Chem., 1990, 265:9062-9065	
\		Corey et al., "Trypsin display on the surface of bacteriophage," Gene, 1993, 128:129-134	
1		Cota, E., et al., "Two proteins with the same structure respond very differently to mutation: The role of plasticity", J. Mol. Biol., vol. 302, 713-725, (2000)	
		Cota and Clarke, Protein Sci., 2000, 9:112-120	
,		Creighton, Proteins: structures and molecular properties, 1993, Freeman New York, pp.38-40	
		Davies and Riechmann, "Single antibody domains as small recognition units: design and in vitro antigen selection", Protein Eng., 1996, 9(6):531-537	
۸.		Davies, J., et al., "Antibody VH Domains as Small Recognition Units", Bio/Technol., 13, 475-479 (1995).	
1		Delaglio et al., "NMRPipe: a multidimensional spectral processing system based on UNIX pipes," J. Biomol. NMR, 1995, 6:277-293	
		Deng and Nickoloff, "Site-directed mutagenesis of virtually any plasmid by eliminating a unique site," Anal. Biochem., 1992, 200:81-88	

	Examiner T.D.	Date Considered	10/16/05
--	---------------	-----------------	----------

^{*}EXAMINER: Initial if reference considered, whether or that citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

considered. Include copy of this form with next communication to applicant.

1 Applicant's unique citation designation number (optional). 2 Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

Approved for use through 07/31/2006, OMB 0651-0031

17027.003US1

Under the Paperwork Reduction Act of 1995, no persons an	e required to respond to a collection	on of information unless it contains a valid OMB control number.
ubstitute for form 1449/PTO		Complete if Known
	Application Number	09/903,412
NFORMATION DISCLOSURE	Filing Date	July 11, 2001
STATEMENT BY APPLICANT	First Named Inventor	Shohei Koide
. (Use as many sheets as necessary)	Art Unit	1639
	Examiner Name	Teresa D. Wessendorf

Attorney Docket Number

Sheet

of 25

		NON PATENT LITERATURE DOCUMENTS	
Examine Initials*	Cite No.1	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
Ton		de Prat Gay and Fersht, "Generation of a family of protein fragments for structure-folding studies," Biochemistry, 1994, 33:7957-7963	
,		Desiderio, A., et al., "A semi-synthetic repertoire of intrinsically stable antibody fragments", J. Mol. Biol., vol. 310, pp. 603-615 (2001)	
		de Vos et al., "Human Growth hormone and extracellular domain of its receptor: crystal structure of the complex," Science, 1992, 255:306-312	
		Dickinson et al., "Crystal structure of the tenth type III cell adhesion module of human fibronectin," J. Mol. Biol., 1994, 236, 1079-1092	
1.		Dill, Biochemistry, 1990, 29:7133-7155	
		Djavadi-Ohaniance et al., Antibody Engineering. A Practical Approach, (McCafferty et al., Ed.), pp. 77-97, Oxford Univ. Press, Oxford	
,		Doolittle, R.F., "The multiplicity of domains in proteins", Annu. Rev. Biochem., vol. 64, 287-314, (1995).	
l		Dougall, W.C., et al., "Antibody-structure-based design of pharmacological agents", Trends in Biotechnology, 12, 372-379 (1994).	
!		Duttweiler, "A highly sensitive and non-lethal •-galactosidase plate assay for yeast," Trends in Genetics, 1996, 12:340-341	
		Dwyer et al., "High Affinity RNase S-peptide Variants Obtained by Phage Display Have a Novel "Hot-Spot" of Binding Energy," Biochemistry, 2001, 40:13491-13500	

E			
Examiner	$+$ \sim \sim	Date	C . 1
Cianatura		Date	10 10/1
Signature	1.0.	Considered	10/20/65
*EVAMINED. I	Hal Madaman savidand to the Colorest	Solisidered	

^{*}EXAMINER: Initial if reference considered, whether or not/citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

considered. Include copy or this form with next communication to applicant.

1 Applicant's unique citation designation number (optional). 2 Applicant is to place a check mark here if English language Translation is attached.

This collection of Information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the Individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO:

Approved for use through 07/31/2006. OMB 0651-0031
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

	ite for form 1449/PTO	uction A	ct or 1995, no persons a	e required to respond to a collection	of information unless it contains a valid OMB co	ontrol number.
002000				Application Number	09/903,412	
			CLOSURE	Filing Date	July 11, 2001	
STATEMENT BY APPLICANT				First Named Inventor	Shohei Koide	
	(Use as many sheets as necessary)		Art Unit	1639	<u> </u>	
	., (000 00			Examiner Name	Teresa D. Wessendorf	
Sheet	8	of	25	Attorney Docket Number	17027.003US1	

		NON PATENT LITERATURE DOCUMENTS	
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T²
TOW		Ely, K.R., et al., "Common Molecular Scaffold for Two Unrelated RGD Molecules", Protein Engineering, 8, 823-827 (1995).	
		Farrow et al., "Backbone dynamics of a free and phosphopeptide-complexed Src homology 2 domain studied by 15N NMR relaxation," Biochemistry, 1994, 33:5984-6003	
		Fields and Song, "A novel genetic system to detect protein-protein interactions," Nature, 1989, 340:245-246	
		Finley and Brent, "Interaction mating reveals binary and ternary connections between Drosophila cell cycle regulators," Proc Natl Acad Sci USA, 1994, 91:12980-12984	
•		Fujiwara et al., "A single-chain antibody/epitope system for functional analysis of protein-protein interactions, Biochemistry, 2002, 41:12729-12738	
٩		Garrett et al., "A common sense approach to peak picking in two-, three-, and four-dimensional spectra," J. Magn. Reson.,1991, 95:214-220	
		Geyer and Brent, "Selection of genetic agents from random peptide aptamer expression libraries," Methods Enzymol., 2000, 328:171-208	
,		Ghosh et al., "Structure of NF-kB p50 homodimer bound to a kB site," Nature, 1995, 373:303-310	
ļ		Golemis and Serebriiskii, "Two-hybrid system/interaction trap," Cells: A laboratory manual, 1997, 69:1-40, CSH Laboratory Press, Cold Spring Harbor, NY	
J,		Green, S.M., et al., "Contributions of the polar, uncharged amino acids," Biochemistry, 31(25), 5717-5728, (1992).	

Examiner	1 ()		Doto			
	+ $()$		Date		12/2/01	
Signature		//	Considered	10	100101	
*EYANIMED: In	Wal Manfaganaga against description of the state					

^{*}EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

considered. Include copy of this form with next communication to applicants is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO:

Approved for use through 07/31/2006. OMB 0651-0031 U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Substitute for form 1449/PTO					Complete if Known	
				Application Number	09/903,412	
INF	ORMATION	I DIS	SCLOSURE	Filing Date	July 11, 2001	
STA	ATEMENT E	3Y A	PPLICANT	First Named Inventor	Shohei Koide	
	(Use as many she	ets as i	necessary)	Art Unit	1639	
	(550 55 11111)			Examiner Name	Teresa D. Wessendorf	
Sheet	9	of	25	Attorney Docket Number	17027.003US1	

Examiner	Cite	NON PATENT LITERATURE DOCUMENTS Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of	
nitials*	No.1	the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	7
TOU		Gribskov et al., "The codon preference plot: graphic analysis of protein coding sequences and prediction of gene expression," Nuc. Acids. Res., 1984, 12:539-549	
)		Grimsley et al., Protein Sci., 1999, 8:1843-1849	
		Gronenborn et al., "A novel, highly stable fold of the immunoglobulin binding domain of Streptococcal protein G," Science, 1991, 253:657-661	
		Gronenborn and Clore, "Identification of the contact surface of a Streptococcal protein G domain complexed with a human Fc fragment," J. Mol. Biol., 1993, 233:331-335	
		Grumet et al., The Journal of Cell Biology 113:1399-1412, 1991.	
		Grzesiek et al., "Correlation of backbone amide and aliphatic side-chain resonances in 13C/15N-enriched proteins," J. Magn. Reson. B, 1993, 101:114-119	
<u> </u>		Grzesiek and Bax, "Correlating backbone amide and side chain resonances in larger proteins by multiple relayed triple resonance NMR," J. Am. Chem. Soc., 1992, 114:6291-6293	
,		Grzesiek and Bax, "Amino acid type determination in the sequential assignment procedure of uniformly 13C/15N-enriched proteins," J. Biomol. NMR, 1993, 3:185-204	
,		Gyuris et al., "Cdil, a human Gl and S phase protein phosphatase that associates with Cdk2," Cell, 1993, 75:791-803	
\bigvee		Harpez and Chothia, "Many of the immunoglobulin superfamily domains in cell adhesion molecules," Mol. Biol., 1994, 238:528-539	

Examiner	$+$ \sim	Date	
Signature		Considered /	0/6/05

^{*}EXAMINER: Initial if reference considered, whether or not displan is in conformance with MPEP 609. Draw line through citation if hot in conformance and not considered. Include copy of this form with next communication to applicant.

1 Applicant's unique citation designation number (optional). 2 Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

Substitute for form 1449/PTO				Complete if Known		
				Application Number	09/903,412	
			SCLOSURE	Filing Date	July 11, 2001	
STA	ATEMENT B	BY A	PPLICANT	First Named Inventor	Shohei Koide	
	(Use as many sho	eets as r	iecessan/)	Art Unit	1639	
				Examiner Name	Teresa D. Wessendorf	
Sheet	10	of	25	Attorney Docket Number	17027.003US1	

		NON PATENT LITERATURE DOCUMENTS	
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
tau		Hawkins et al., "The contribution of contact and non-contact residues of antibody in the affinity," Mol. Biol., 1993, 234:958-964	
		Hawkins et al., "Selection of phage antibodies by binding affinity. Mimicking affinity maturation," J. Mol. Biol., 1992, 226:889-896	
1		Helms et al., Protein Science 4:2073-81, 1995.	
e		Helms et al., Protein Science, "Proteolytic excision and in situ cyclization of a bioactive loop from an REI-VL presentation scaffold," 3:1108-1113 (1994).	
)		Hendsch et al., Biochemistry, 1996, 35:7621-7625	
(Hendsch and Tidor, Protein Sci., 1994, 3:211-226	
		Hennecke et al., "Random circular permutation of DsbA reveals segments that are essential for protein folding and stability," J Mol Biol., 1999, 286:1197-1215	
7		Hoess, "Protein design and phage display," Chem Rev., 2001, 101:3205-3218	
1 .		Holliger, P., et al., ""Diabodies": Small bivalent and bispecific antibody fragments", Proc. Natl. Acad. Sci. USA, 90, 6444-6448 (1993).	
\downarrow		Holm, L. et al., "Mapping the protein universe", Science, vol. 273, p. 595-602, (Aug. 2, 1996).	

Examiner	+ 0	Date	
Signature	- , , , , , , , , , , , , , , , , , , ,	Considered	10/26/25
*EYAMINED: In	Mal Manfarance as a state of the state of th		

if reference considered, whether or not citation if in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

considered. Include copy of this form with next communication to applicant.

1 Applicant's unique citation designation number (optional). 2 Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO:

Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

Approved for use through 07/31/2006. OMB 0651-0031 U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

	Substitute for form 1449/PTO		required to respond to a collection of information unless it contains a valid QMB control number. Complete if Known		
ĺ				Application Number	09/903,412
	•		SCLOSURE	Filing Date	July 11, 2001
STA	TEMENT E	BY A	PPLICANT	First Named Inventor	Shohei Koide
	(Use as many she	ets as ı	lecessary)	Art Unit	1639
				Examiner Name	Teresa D. Wessendorf
Sheet	11	of	25	Attorney Docket Number	17027.003US1

		NON PATENT LITERATURE DOCUMENTS	
Examiner Initials*	Cite No.1	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
TOW		Holm, L., et al., "FSSP: select structural", Science, 273(5275) :595-60 http://jura.ebi.ac.uk:8765/holm/qz?filename=/data/research/fssp//lfnf. fssp, 3 pages (1996)	
1		Honda et al., "Fragment reconstitution of a small protein: folding energetics of the reconstituted immunoglobulin," Biochemistry, 1999, 38:1203-1213	
		Hu, S., et al., "Minibody: A Novel Engineered Anti-Carcinoembryonic Antigen Antibody Fragment (Single-Chain Fv-CH3)", Cancer Research, 56, 3055-3061 (1996).	
		Ikura and Bax, "Isotope-filtered 2D NMR of a protein-peptide complex: study of a skeletal muscle myosin," J. Am. Chem. Soc., 1992, 114:2433-2440	
		Ikura et al., "Improved three-dimensional 1H-13C-1H correlation spectroscopy of a 13C-labeled protein using constant-time evolution," J. Biomol. NMR, 1991, 1:299-304	
•		Jacobs and Schultz, "Catalytic antibodies," J. Am. Chem. Soc., 1987, 109:2174-2176	
		Janda, K.D., et al., "Chemical Selection for Catalysis in Combinatorial Antibody Libraries", Science, 275, 945-948 (1997).	
ŧ		Johnson and Blevins, J. Biomol. NMR, 1994, 4:603-614	
,		Johnsson and Varshavsky, "Split ubiquitin as a sensor of protein interactions in vivo," Proc Natl Acad Sci USA, 1994, 91:10340-10344	
\downarrow		Jones, "The immunoglobulin superfamily," Curr. Opinion Struct. Biol., 1993, 3:846-852	

Examiner Signature	T.D. 7	Date Considered	10/26/08
*EVAMINED. In	in if mforence considered whether a set it is the		

^{*}EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

1 Applicant's unique citation designation number (optional). 2 Applicant is to place a check mark here if English language Translation is attached.

This collection of Information is required by 37 CFR 1.98. The Information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT Sections for COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

PTO/SB/08B (07-05) Approved for use through 07/31/2006. OMB 0651-0031

	U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE
Under the Paperwork Reduction Act of 1995	no persons are required to respond to a collection of information unless it contains a valid OMR control number

Substit	ute for form 1449/PTO			Complete if Known		
·				Application Number	09/903,412	
INF	ORMATION	I DIS	CLOSURE	Filing Date	July 11, 2001	
STA	ATEMENT B	BY A	PPLICANT	First Named Inventor	Shohei Koide	· · · · ·
	(Use as many sh	aate oe r	ocessar/i	Art Unit	1639	
	(ooc as many on		ocussary)	Examiner Name	Teresa D. Wessendorf	
Sheet	12	of	25	Attorney Docket Number	17027.003US1	

		NON PATENT LITERATURE DOCUMENTS	
Examiner Cite No.1		Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T²
THU	_	Jones et al., "Replacing the complementarity-determining regions in a human antibody with those from a mouse," Nature, 1986, 321:522-525	
		Jourdan and Searle, "Cooperative assembly of a nativelike ubiquitin structure through peptide fragment complexation," Biochemistry, 2000, 39:12355-123640	
		Kabsch and Sander, "Dictionary of protein secondary structure: pattern recognition of hydrogen-bonded and geometrical features," Biopolymers, 1983, 22:2577-2637	
j		Kamtekar et al., "Protein design by binary patterning of polar and nonpolar amino acids," Science, 1993, 262(5140):1680-1685	
		Kapust et al., "Tobacco etch virus protease: mechanism of autolysis and rational design of stable mutants with wildtype catalytic proficiency," Protein Eng., 2001, 14:993-1000	
١		Kauzmann, Adv. Prot. Chem., 1959, 14:1-63	
		Kay, "Field gradient techniques in NMR spectroscopy," Curr. Opinion Struct. Biol., 1995, 5:674-681	
(Kay et al., "Pure absorption gradient enhanced heteronuclear single quantum correlation spectroscopy with improved sensitivity," J. Am. Chem. Soc., 1992, 114:10663-10665	
		Kay et al., "Backbone dynamics of proteins as studied by 15N inverse detected heteronuclear NMR spectroscopy," Biochemistry, 1989, 28:8972-8979	
*		Kay, "Pulsed-Field Gradient-Enhanced Three-Dimensional NMR Experiment for Correlating," J. Am. Chem.Soc. 1993, 115:2055-2057.	

Examiner Signature	T.O. 7	Date Considered	10/16/08
ACVALUED .	21.12		

[&]quot;EXAMINER: Initial if reference considered, whether or not diation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

1 Applicant's unique citation designation number (optional). 2 Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

	ute for form 1449/PTO		ct of 1993, no persons an	Complete if Known		
				Application Number	09/903,412	
			CLOSURE	Filing Date	July 11, 2001	
STA	ATEMENT E	BY A	PPLICANT	First Named Inventor	Shohei Koide	
	(Use as many she	ets as n	ecessarvi	Art Unit	1639	
·				Examiner Name	Teresa D. Wessendorf	
Sheet	13	of	25	Attorney Docket Number	17027.003US1	

xaminer nitials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	Т
for		Kay et al., "A Gradient-Enhanced HCCH-TOCSY Experiment for Recording Side-Chain 1H and 13C Correlations in H2O Samples of Proteins," J. Magn. Reson. B, 1993, 101:333-337	
a		Kippen et al., "Folding of barnase in parts," Biochemistry, 1994, 33:3778-3786	
		Kohno et al., "A new general method for the biosynthesis of stable isotope-enriched peptides using a decahistidine-tagged," J. Biomol. NMR, 1998, 12:109-121	
		Koide et al., "Characterization of a folding intermediate of apoplastcyanin trapped by proline isomerization," Biochemistry, 1993, 284:12299-12310	
		Koide et al., "The fibronectin type III domain as a scaffold for novel binding proteins," J. Mol. Biol., 1998, 284:1141-1151	
4		Koide, S., et al., "Directed Evolution", Dept. of Biochemistry and Biophysics, University of Rochester Medical Center, Rochester, NY 14642. FASEB J. 11 No. 9, PA1155 (1997)	-
		Koide et al., Biochemistry 1999, 38:4757-4767	
4		Koide et al., "Stabilization of a fibronectin type III domain by the removal of unfavorable electrostatic," Biochemistry, 2001, 40:10326-10333	

Examiner \ \ \ \ \ \ \ \ \ \ \ \ \ \ \ \ \ \ \	Date	10 6 1
Signature 1 1 1 2 - /	Considered	10/2/05

[&]quot;EXAMINER: Initial if reference considered, whether of not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered, include copy of this form with next communication to applicant.

1 Applicant's unique citation designation number (optional). 2 Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

17027.003US1

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number. Complete if Known Substitute for form 1449/PTO **Application Number** 09/903,412 INFORMATION DISCLOSURE **Filing Date** July 11, 2001 STATEMENT BY APPLICANT First Named Inventor Shohei Koide Art Unit 1639 (Use as many sheets as necessary) **Examiner Name** Teresa D. Wessendorf

Attorney Docket Number

Sheet

14

25

	No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T²
TOW		Koide et al., "Probing protein conformational changes in living cells by using designer binding proteins: Application to the estrogen receptor," PNAS, 2002, 99:1253-1258	
1		Komblihtt et al., "Primary structure of human fibronectin: differential splicing may generate at least 10 polypeptides from a single gene," EMBO J., 1985, 4:1755-1759	
C		Kraulis, "MOLSCRIPT: a program to produce both detailed and schematic plots of protein structures" J. Appl. Cryst., 1991, 24:946-950	
		Kuhlman et al., Biochemistry, 1999, 38:4896-4903	
		Kunkel, "Rapid and efficient site-specific mutagenesis without phenotypic selection." Proc. Natl. Acad. Sci. USA, 1985, 82:488-492	
,		Ladurner et al., "Complementation of peptide fragments of the single domain protein chymotrypsin inhibitor 2," J Mol Biol., 1997, 273:317-329	
`		Lazar et al., Molecular and Cellular Biology 8:1247-1252, 1988. 8(3):1247-1252	
,		Leahy et al., Cell, 1996, 84:155-164	
1		Leahy et al., "Structure of a fibronectin type III domain from tenascin phased by MAD analysis of the selenomethionyl protein," Science, 1992, 258:987-991	<u> </u>

Examiner	./\ _ /\	Date	. / /
		Date	12/16/20
Signature	$1 - 11 \cdot 9$	Considered	10/00/00
- ignature		Considered	/ / 0 -

^{*}EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). 2 Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

Substitu	te for form 1449/PTO			Complete if Known		
				Application Number	09/903,412	
INF	ORMATION	DIS	CLOSURE	Filing Date	July 11, 2001	
STA	ATEMENT E	BY A	PPLICANT	First Named Inventor	Shohei Koide	-
	(Use as many she	ate se r	locacean/	Art Unit	1639	
(See as many another as maces any)				Examiner Name	Teresa D. Wessendorf	
Sheet	15 ·	of	25	Attorney Docket Number	17027.003US1	

		NON PATENT LITERATURE DOCUMENTS	
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T²
Tav		Lee, G., et al., "Strong Inhibition of Fibrinogen Binding to Platelet Receptor .alpha sub.llb.betasub.3 by RGD Sequences", Protein Enineering, 6, 745-754 (1993).	
^		Lee et al., "Three-dimensional solution structure of a single zinc finger DNA-binding domain," Science, 1989, 245:635-637	
		Lee et al., "A pulsed field gradient isotope-filtered 3D 13C HMQC-NOESY experiment for extracting intermolecular NOE contacts," FEBS Lett., 1994, 350:87-90	
j		Lerner, R.A., et al., "Using the Proces of Reactive Immunization to Induce Catalytic Antibodies", Acta Chemica Scandinavica, 50, 672-677 (1996).	
		Li, B., et al., "Minimization of Polypeptide Hormone", Science, 270, 1657-1660 (1995). Martin, F., et al., "The affinity-selection", EMBO J., 13, 5303-5309 (1994).	
		Lin et al., Biochemistry 14:1559-1563, 1975	
Ü		Litvinovich et al., "Reversible unfolding of an isolated heparin and DNA binding fragment the first type III module from fibronectin," Biochim. Biophys. Acta, 1992, 1119:57-62	
٨		Logan et al., "Side chain and backbone assignments in isotopically labeled proteins from two heteronuclear triple resonance experiments," FEBS Lett., 1992, 314,:413-418	
(Loladze et al., Biochemistry, 1999, 38:16419-16423	
V		Lowman et al., Biochemistry, 1991, 30:10832-10838	

Examiner	→ ∧	Date	1
		Date	13/2/
Signature	1 1 (1) /	Considered	10176105
		Considered	1 1 1 7 7 7 9

^{*}EXAMINER: Initial if reference considered, whether or noticitation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

1 Applicant's unique citation designation number (optional). 2 Applicant is to place a check mark here if English language Translation is attached. This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO:

Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

Approved for use through 07/31/2006. OMB 0651-0031

Hedertha Dansound Dad att. A 4 4 400	U.S. Patent and Trademark Office:	U.S. DEPARTMENT OF COMMERCE
Under the Paperwork Reduction Act of 1995, no persons are re	quired to respond to a collection of information unless it	contains a valid OMB control augustan

	ute for form 1449/P				n of information unless it contains a valid OMB control number. Complete if Known
[Application Number	09/903,412
			SCLOSURE	Filing Date	July 11, 2001
STA	ATEMENT	BYA	PPLICANT	First Named Inventor	Shohei Koide
	(Use as many	sheets as r	nacessarvi	Art Unit	1639
				Examiner Name	Teresa D. Wessendorf
Sheet	16	of	25	Attorney Docket Number	17027.003US1

Exam	iner	Cite	NON PATENT LITERATURE DOCUMENTS	
nitial		No.1	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T
10	N		Main et al., "The three-dimensional structure of the tenth type III module of fibronectin: an insight into RGD-mediated interactions," Cell, 1992, 71:671-678	
1			Malakauskas and Mayo, Nat Struct Biol., 1998, 5:470-475	
િ			Marti-Renom, M.A., et al., "Comparative protein structure modeling of genes and genomes", Annu. Rev. Biophys. Biomol. Struct., vol. 29, 291-325, (2000).	
. <	9 7	_	Martin, M.T., "The Affinity-selection of minibody polypeptide inhibitor of human interleukin-6", EMBO J 13:5303-5309 (1994).	
	W.		Martin, M.T., "Commercially valuable catalytic antibodies: The life to come", Drug Discovery Today, 1, 239-247 (1996).	
	,		Masat, L., et al., "A simpler sort of antibody", Proc. Natl. Acad. Sci. USA, 91, 893-896 (1994).	
1			Matthews, B.W., "Structural and genetic analysis of protein stability", Annu. Rev. Biochem., vol. 62, 139-60, (1993).	
1			McCafferty et al., "Phage antibodies: filamentous phage displaying antibody variable domains," Nature, 1990, 348:552-554	
1			McClain et al., "Design and Characterization of a Heterodimeric Coiled Coil that Forms Exclusively," J. Am. Chem. Soc., 2001, 123:3151-3152	
\bigvee			McConnell, S.J., et al., "Tendamistat as a Scaffold", Journal of Mol. Biol., 250, 460-470 (1995).	

Evernines		
Examiner	Date	
Cianatura	Date	1 / ,
Signature J · / _ / _ /	// Considered	10/26/25
*FYAMINED: Initial if reference country	Collsidered	1 (0/24//)

^{*}EXAMINER: Initial if reference considered, whether or not chation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

considered. Include copy of this form with next communication to applicant.

1 Applicant's unique citation designation number (optional). 2 Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO:

PTO/SB/08B (07-05) Approved for use through 07/31/2006. OMB 0651-0031

U.S. Patent and Trademark C	Mica: IIS DEPARTMENT	JE COMMEDCE
Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unit	Jane it contains a self-field fit	OF COMMERCE

	ute for form 1449/PTO				n of information unless it contains a valid OMB control number. Complete if Known
.				Application Number	09/903,412
			SCLOSURE	Filing Date	July 11, 2001
STA	ATEMENT E	3Y A	PPLICANT	First Named Inventor	Shohei Koide
	(Use as many she	ets as i	necessary)	Art Unit	1639
				Examiner Name	Teresa D. Wessendorf
Sheet	17	of	25	Attorney Docket Number	17027.003US1

Funning		NON PATENT LITERATURE DOCUMENTS	
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
TO		Merkel and Regan, "Modulating protein folding rates in vivo and in vitro by side-chain interactions between the parallel beta strands," J Biol Chem., 2000, 275:29200-29206	
·		Metzler et al., "The three-dimensional solution structure of the SH2 domain from p55blk kinase," Biochemistry, 1996, 35:6201-6211	
		Michnick et al., "Detection of protein-protein interactions by protein fragment complementation strategies," Methods Enzymol., 2000, 328:208-230	
ı		Minor and Kim, "Measurement of the •-sheet-forming propensities of amino acids," Nature, 1994, 367:660-663	
		Muhandiram et al., "An enhanced-sensitivity pure absorption gradient 4D 15N,13C-edited NOESY experiment," J. Biomol. NMR, 1993, 3:463-470	
1		Muller et al., "Structure of the NH-kB p50 homodimer bound to DNA," Nature, 1995, 373:311-117	
Q		Myers et al., Protein Sci., 1995, 4:2138-2148	
		Nicholls et al., "Protein folding and association: insights from the interfacial and thermodynamic properties of hydrocarbons," Proteins, 1991, 11:281-296	
		Nilges et al., "Determination of three-dimensional structures of proteins", FEBS Lett., 1988, 229:317-324	
\downarrow		Nilges et al., Computational aspects of the study of biological macromolecule, 1991, (Hoch, J. C., Poulsen, F. M. and Redfield, C., Ed.), pp. 451-455, Plenum Press, New York	
			<u> </u>

Signature T () Considered 10 /26/01	Examiner	- 0 01	Data	
Considered	•	T (1) · 1)	Date	12 /21/
*EVAMINED. In the state of the		1 1 1	Considered	10/26/01

Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

considered. Include copy or this form with next communication to applicant.

1 Applicant's unique citation designation number (optional). 2 Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SERS OF COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

Approved for use through 07/31/2006, OMB 0651-0031 U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE
Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number

	ute for form 1449/PTO				n of information unless it contains a valid OMB control number. Complete if Known
				Application Number	09/903,412
			CLOSURE	Filing Date	July 11, 2001
STA	ATEMENT E	BY A	PPLICANT	First Named Inventor	Shohei Koide
	(Use as many she	sets as r	lecessary)	Art Unit	1639
				Examiner Name	Teresa D. Wessendorf
Sheet	18	of	25	Attorney Docket Number	17027.003US1

		NON PATENT LITERATURE DOCUMENTS	
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T²
you		Ojennus et al., "Reconstitution of a native-like SH2 domain from disordered peptide fragments examined bymultidimensional," Protein Science, 2001, 10:2162-2175	
4		Oakley et al., "A buried polar interaction can direct the relative orientation of helices in a coiled coil," Biochemistry, 1998, 37:12603-12610	
		O'Neil et al., Techniques in Protein Chemistry V, 1994, (Crabb, L., ed.) pp. 517-524, Academic Press, San Diego	
		O'Neil and Hoess, "Phage display: protein engineering by directed evolution," Curr. Opinion Struct. Biol., 1995, 5:443-449	
		Pabo et al., "Design and selection of novel Cys2His2 zinc finger proteins," Annu Rev Biochem., 2001, 70:313-340	
		Pace and Scholtz, "Measuring the conformational stability of a protein," Protein structure. A practical approach, 1997, (Creighton, T. E. Ed.) pp. 299-321, IRL Press, Oxford	
		Pace et al., Faseb J., 1996, 10:75-83	
ı		Pace et al., Biochemistry, 1992, 31:2728-2734.	
		Parmley et al., "Antibody-selectable filamentous fd phage vectors: affinity purification of target genes," Gene, 1988, 73:305-318	
		Pascal et al., "Nuclear magnetic resonance structure of an SH2 domain of phospholipase C-gl complexed with a high affinity binding peptide," Cell, 1994b, 77:461-472	

Examiner	+ 10 11	Date 6. (
Signature			
Oignature		Considered 10/20/03	

^{*}EXAMINER: Initial if reference considered, whether or not obtains is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Considered, include copy or this form with next communication to applicant.

1 Applicant's unique citation designation number (optional). 2 Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO:

Approved for use through 07/31/2006. OMB 0651-0031
S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons ar	e required to respond to a collection	of information unless it contains a valid OMB control nur	EKCE mber.
stitute for form 1449/PTO		Complete if Known	
	Application Number	09/903 412	

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Use as many sheets as necessary)

of 25

Sheet 19

	Complete if Known	
Application Number	09/903,412	
Filing Date	July 11, 2001	
First Named Inventor	Shohei Koide	
Art Unit	1639	
Examiner Name	Teresa D. Wessendorf	
Attorney Docket Number	17027.003US1	

		NON PATENT LITERATURE DOCUMENTS	
Examiner Initials*	Cite No.1	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T
TW		Pascal et al., "Simultaneous acquisition of 15N-and 13C-edited NOEspectra of proteins dissolved in H2O," J. Magn. Reson. B, 1994a, 103:197-201	
		Patten et al., "Applications of DNA shuffling to pharmaceuticals and vaccines," Curr. Opin. Biotechnol. 1996, 8:724-733	
		Pelletier et al., "Oligomerization domain-directed reassembly of active dihydrofolate reductase from rationally designed fragments," Proc. Natl. Acad. Sci. USA, 1998, 95:12141	
ι		Perl et al., "Two exposed amino acid residues confer thermostability on a cold shock protein," Nat Struct Biol., 2000, 7:380-383	
		Perutz et al., J Mol Biol., 1985, 183:491-498	
(Pessi, A., et al., "A designed metal-binding protein with a novel fold", Nature, 362, 367-369 (1993).	
(Pierschbacher and Ruoslahti, Nature, 1984, 309:30-33	
		Plaxco et al., Proc. Natl. Acad. Sci. USA, 1996, 93:10703-10706	
		Plaxco et al., J. Mol. Biol., 1997, 270:763-770	
W.		Rader and Barbas, "Phage display of combinatorial antibody libraries," Curr Opin Biotechn., 1997, I8:503-508.	-

Examiner Signature	T.D. ~	Date Considered	10/26/05
ALVARABLES.	TALLED IN THE PROPERTY OF THE PARTY OF THE P		

^{*}EXAMINER: Initial if reference considered, whether or not bijution is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

considered. Include copy of this form with next communication to applicant.

1 Applicant's unique citation designation number (optional). 2 Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SED FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO:

Approved for use through 07/31/2006. OMB 0551-0031

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number. Complete if Known Substitute for form 1449/PTO **Application Number** 09/903,412 Filing Date July 11, 2001 First Named Inventor Shohei Koide Art Unit

INFORMATION DISCLOSURE STATEMENT BY APPLICANT 1639 ' (Use as many sheets as necessary) **Examiner Name** Teresa D. Wessendorf **Attorney Docket Number** 20 25 17027.003US1

Examiner	Cite	NON PATENT LITERATURE DOCUMENTS Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of	т —
Initials*	No.1	the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
ph		Raquet et al., "Detection of altered protein conformations in living cells," J Mol Biol., 2001, 305:927-938	
8		Rees et al., "Antibody design: beyond the natural limits," Trends Biotechnol., 1994, 12:199-206	
		Roberts et al. Proc. Natl. Acad. Sci. USA, 1992, 89:2429-2433	
		Roberts et al., "Affinity maturation of proteins displayed on surface of M13 bacteriophage as major coat protein fusions," Methods Enzymol., 1996, 267:68-82	
1		Rosenblum, J.S., et al., "Synthetic Antibodies", Antibody Engineering, Oxford University Press, Oxford, 89-116 (1995).	
,		Suzuki, H., "Recent Advances in Abzyme Studies", J. Biochem., 115, 623-628 (1994).	
ı		Sali et al., J. Mol. Biol., 1991, 220:779-788	
		Sancho and Fersht, "Dissection of an enzyme by protein engineering," J Mol Biol., 1992, 224:741-747	
		Sandhu et al., "Dual asymmetric PCR: onestep construction of synthetic genes," BioTech., 1992, 12:14-16	
$\sqrt{}$	_	Santoro and Bolen, "Unfolding free energy changes determined by the linear extrapolation method. 1", Biochemistry, 1988, 27:8063-8068	

Examiner Signature	T.D.	Date Considered	10/26/05

^{*}EXAMINER: Initial if reference considered, whether of hot citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

considered. Include copy of this form with next communication to applicant.

1 Applicant's unique citation designation number (optional). 2 Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

PTO/SB/08B (07-05)
Approved for use through 07/31/2006. OMB 0651-0031
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE
a collection of Information unless it contains a waite OMB page 11

Substitu	ite for form 1449/PTO			Complete if Known		
				Application Number	09/903,412	
INF	ORMATION	I DIS	SCLOSURE	Filing Date	July 11, 2001	
STA	ATEMENT B	BY A	PPLICANT	First Named Inventor	Shohei Koide	
	(Use as many sho	aate as	nacesand	Art Unit	1639	
	lose as many and	0013 23 1	incessary)	Examiner Name	Teresa D. Wessendorf	
Sheet	21	of	25	Attorney Docket Number	17027.003US1	

		NON PATENT LITERATURE DOCUMENTS	
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T²
THU		Savchenko et al., "Pyrococcus furiosus alpha-Amylase Is Stabilized by Calcium and Zinc," Biochemistry, 2002, 41:6193-6201	
		Sblattero and Bradbury, "Exploiting recombination in single bacteria to make large phage antibody libraries," Nat Biotechnol., 2000, 18:75-80	
		Sblattero et al., "In vivo recombination as a tool to generate molecular diversity in phage antibody libraries," Biotechnol., 2001, 74:303-315	
t		Schiweck, W., et al., "The rational construction of an antibody against cystatin", J. Mol. Biol., vol. 268, 934-951, (1997).	
		Schwartz et al., Proc. Natl. Acad. Sci. USA 84:6408-6411, 1987.	
,		Shortle, D., et al., "Contributions of the large hydrophobic amino acids to the stability of staphylococcal nuclease", Biochemistry, vol. 29, 8033-8041, (1990).	
		Shusta, E.V., et al., "Directed evolution of a stable scaffold for T-cell receptor engineering", Nature Biotechnology, vol. 18, pp. 754-759 (Jul. 2000).	
		Skerra, "Engineered protein scaffolds for molecular recognition," J Mol Recognit, 2000, 13:167-187	
		Smith and Scott, "Libraries of peptides and proteins displayed on filamentous phage," Methods Enzymol., 1993, 217:228-257	

Examiner Signature	·D. ~,	Date Considered	10/16/05
4514454155			

^{*}EXAMINER: Initial if reference considered, whether or not estation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

considered, include copy of this form with next communication to applicant.

1 Applicant's unique citation designation number (optional). 2 Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

Approved for use through 07/31/2006. OMB 0651-0031 U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

	ute for form 1449/PTO		act or 1995, no persons a	Complete if Known		
				Application Number	09/903,412	
			SCLOSURE	Filing Date	July 11, 2001	
STA	ATEMENT E	BY A	PPLICANT	First Named Inventor	Shohei Koide	
	(Use as many she	ote se i	nocessar/i	Art Unit	1639	
	(OGC GO IIAII) SIII			Examiner Name	Teresa D. Wessendorf	
Sheet	22	of	25	Attorney Docket Number	17027.003US1	

		NON PATENT LITERATURE DOCUMENTS	
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T²
TOW		Smith, "Filamentous fusion phage: novel expression vectors that display cloned antigens on the virion surface," Science, 1985, 228:1315-1317	
		Smith and Regan, "Guidelines for protein design: The energetics of • sheet side chain interactions," Science, 1995, 270:980-982	
l l		Smith et al., "Studying a-helix and •-sheet formation in small proteins," Techniques Prot. Chem., 1995, 6:323-332	
		Smith et al., "A thermodynamic scale for the •-sheet forming tendencies of the amino acids," Biochemistry, 1994, 33:5510-5517	
		Smyth and von Itzstein, "Design and synthesis of a biologically active antibody mimic based on an antibody-antigen crystal structure," Am. Chem. Soc., 1994, 116:2725-2733	
1		Spector et al., Biochemistry, 2000, 39:872-879	
٨		Studier et al., "Use of T7 RNA polymerase to direct expression of cloned genes," Methods Enzymol., 1990, 185:60-89	
<i>*</i>		Suzuki, "Recent advances in abzyme studies," J. Biochem., 1994, 115:623-628	
ŧ		Tasayco and Chao, "NMR study of the reconstitution of the beta-sheet of thioredoxin by fragment complementation," Proteins, 1995, 22:41-44	
V		Tasayco et al., "Interaction between two discontiguous chain segments," Biochemistry, 2000, 39:10613-10618	

Examiner T ()	Date 106	
Signature / /	Considered Volo	

^{*}EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

considered. Include copy of this form with next communication to applicant.

1 Applicant's unique citation designation number (optional). 2 Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEDD FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERC!

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERC!

	ite for form 1449/PTO		act of 1995, no persons a	Complete if Known		
				Application Number	09/903,412	
			SCLOSURE	Filing Date	July 11, 2001	
STA	TEMENT E	BY A	PPLICANT	First Named Inventor	Shohei Kolde	
	(Use as many she	ate ae i	าควรรอกส	Art Unit	1639	
	(Coo do many and			Examiner Name	Teresa D. Wessendorf	
Sheet	23	of	25	Attorney Docket Number	17027.003US1	

_		NON PATENT LITERATURE DOCUMENTS	
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T²
TOW	·	Tello et al., "Immunoglobulin superfamily interactions," Biochem. Soc. Trans., 1993, 21:943-946	
,		Thomas, N.R., "Hapten Design for the Generation of Catalytic Antibodies", Applied Biochemistry and Biotechnology, 47, 345-372 (1994).	
,	0	Timasheff, Curr. Op. Struct. Biol., 1992, 2:35-39	
1		van den Beucken, T., "Building novel binding ligands to B&.1 and B&.2 based on human antibody single variable light chain domains", J. Mol. Biol., vol. 310, pp. 591-601 (2001)	
I		Verhoeyen et al., "Reshaping human antibodies: Grafting an antilysozyme activity," Science, 1988, 239:1534-1536	
J		Venturini et al., Protein Peptide Letters, 1994, 1:70-75	
		Vuister and Bax, "Resolution enhancement and spectral editing of uniformly 13C-enriched proteins by homonuclear broadband 13C decoupling," J. Magn. Reson., 1992, 98:428-435	
,		Vuister et al., "Increased resolution and improved spectral quality in four-dimensional 13C/13C-separated," J. Magn. Reson. B, 1993, 101:210-213	
١		Ward et al., "Binding activities of a repertoire of single immunoglobulin variable domains secreted from Escherichia coli," Nature, 1989, 341:554-546	
		Webster et al., "Antibody-antigen interactions," Curr. Opinion Struct. Biol., 1994, 4:123-129	

Examiner	TOW	Date	
Signature	$D \cdot D$	Considered	10/26/05

^{*}EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

considered, include copy of this form with next communication to applicant.

1 Applicant's unique citation designation number (optional). 2 Applicant Is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO:

Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

Approved for use through 07/31/2006. OMB 0651-0031 U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO				Complete if Known			
				Application Number	09/903,412		
INF	ORMATION	DIS	SCLOSURE	Filing Date	July 11, 2001		
STA	STATEMENT BY APPLICANT			First Named Inventor	Shohei Koide		
	(Use as many she	ate se i	naceeend	Art Unit	1639		
·				Examiner Name	Teresa D. Wessendorf		
Sheet	24	of	25	Attorney Docket Number	17027.003US1		

	•	NON PATENT LITERATURE DOCUMENTS	
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
TOW		Williams and Barclay, Ann. Rev. Immunol., 1988, 6:381-405	
· ·		Wilson and Stanfield, "Antibody-antigen interactions," Curr. Opinion Struct. Biol., 1993, 3:113-118	
ŧ		Wilson and Stanfield, "Antibody-antigen interactions: new structures and new conformational changes," Curr. Opinion Struct Biol., 1994, 4:857-867	
•		Winter, Greg, "Making Antibodies by Phage Display Technology", Ann. Rev. Immunol., 12, 433-455 (1994).	
· ·		Wiseman et al., "Rapid measurement of binding constants and heats of binding using a new titration calorimeter," Anal. Biolchem., 1989, 179:131-137	
t		Wittenkind and Mueller, "HNCACB, a high-sensitivity 3D NMR experiment to correlate amide-proton", J. Magn. Reson. B, 1993, 101:201-205	
		Wittke et al., "Probing the molecular environment of membrane proteins in vivo," Mol Biol Cell., 1999, 10:2519-2530	
		Wu et al., "Length distribution of CDRH3 in antibodies," Proteins: Struct. Funct. Genet., 1993, 16:1-7	
-		Yamazaki et al., "Segmental Isotope Labeling for Protein NMR Using Peptide Splicing," Journal of the American Chemical Society, 1998, 120(22):5591-5592	
V.		Yamazaki et al., "Two-Dimensional NMR Experiments for Correlating 13C-beta and", J. Am. Chem. Soc., 1993, 115:11054	

|--|

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

considered. Include copy of this form with next communication to applicant.

1 Applicant's unique citation designation number (optional). 2 Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandría, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO:

Commissioner for Patents, P.O. Box 1450, Alexandría, VA 22313-1450.

	ute for form 1449/PT		Act of 1995, no persons a	Complete if Known				
		_		Application Number	09/903,412			
INF	ORMATIO	N DIS	SCLOSURE	Filing Date	July 11, 2001			
STA	ATEMENT	BY A	PPLICANT	First Named Inventor	Shohei Koide			
	(Use as many s	thoots as	noreseand	Art Unit	1639			
		,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,		Examiner Name	Teresa D. Wessendorf			
Sheet	25	of	25	Attorney Docket Number	17027.003US1			

Examiner	Cite	NON PATENT LITERATURE DOCUMENTS Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of	· · · · ·
Initials*	No.1	the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
TRW		Yang and Honig, Curr. Opin. Struct. Biol., 1992, 2:40-45	
(Zhang et al., "Circular permutation of T4 lysozyme," Biochemistry, 1993, 32:12311-12318	
		Zhang et al., "Backbone 1H and 15N resonance assignments of the N-terminal SH3 domain of drk", J. Biomol. NMR, 1994, 4:845-858	
٩		McIntosh et al., Biochemistry, 1996, 35:9958-9966	
		Li et al., "The metal ion binding properties of calreticulin", Biochemistry, 2001, 40, 11193-12201.	
_			
		·	

Examiner	l —— -Λ ——	Date	a C
		Duit	10/2/11
Signature		Considered	10/100
		1 00.13100100	, , , , ,

^{*}EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 809. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

1 Applicant's unique citation designation number (optional). 2 Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

Substitute Form PTO-1449

U.S. Department of Commerce Patent and Trademark Office

Information Disclosure Statement by Applicant

(Use several sheets if necessary)

(37 \$\frac{1}{2} \text{S} \frac{1.98(b)}{2} \

TACK TO THE PARTY OF THE PARTY			U.S. Pate	ent Documents			
Examiner Initial	Desig. ID	Document Number	Publication Date	Patentee	Class	Subclass	Filing Date If Appropriate
	AA	2003/0134386	07/17/2003	Koide			
					_		

	Foreign Patent Documents or Published Foreign Patent Applications								
Examiner [*]	Desig.	Document	Publication	Country or			Transl	ation	
Initial	ַ D	Number	Date	Patent Office	Class	Subclass	Yes	No	
								 	
					_				
	;								
							abstract		

	Other Documents (include Author, Title, Date, and Place of Publication)							
Examiner Initial	Desig. ID	Document						
plu	AB	Dickinson et al., "Active Site Modification of Factor VIIa Affects Interactions of the Protease Domain with Tissue Factor," J. Biol. Chem., 1997, 272:19875-19879						

Examiner Signature	Date Considered
T - iii	10/26/05
1 13	1
EXAMINER: Initials citation considered. Draw line through citation if no	t in conformance and not considered. Include copy of this form with
next communication to applicant.	·